

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (EF-150) ODRONEXTAMAB
 PRONUNCIATION oh" droe nex' ta mab
 THERAPEUTIC CLAIM Treatment of B-cell malignancies

CHEMICAL NAMES

1. Immunoglobulin G4, anti-(human CD20 antigen) (human REGN1979 γ -chain), disulfide with human REGN1979 κ -chain, dimer with immunoglobulin G4, anti-(human CD3 antigen) (human REGN1979 γ -chain), disulfide with human REGN1979 κ -chain
2. Immunoglobulin G4-kappa anti-(*Homo sapiens* B-lymphocyte antigen CD20), hetero dimer with immunoglobulin G4-kappa anti-(*Homo sapiens* T-cell surface glycoprotein CD3 epsilon chain); human monoclonal antibody; γ 4 heavy chain (1-453) [*Homo sapiens* VH (IGHV3-9*01 (95%) –(IGHD)-IGHJ6*01 (95%)) [8.8.20] (1-127) -*Homo sapiens* IGHG4*01 {hinge[S¹⁰>P(235)], CH2[E³>P(240),F⁴>V(241),L⁵>del,G⁶>A(242)]} (128-453)] (141-214')-disulfide with κ light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (98%) –IGKJ4*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')], hetero dimer with γ 4 heavy chain (1"-449") [*Homo sapiens* VH (IGHV3-9*01 (98%) –(IGHD)-IGHJ6*01 (90%)) [8.8.16] (1"-123")-*Homo sapiens* IGHG4*01 {hinge[S¹⁰>P(231")], CH2[E³>P(236"),F⁴>V(237"),L⁵>del,G⁶>A(238")]} (124"-449")] (137"-214"")-disulfide with κ light chain (1""-214""') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (98%) –IGKJ4*01)[6.3.9] (1""-107""') -*Homo sapiens* IGKC*01 (108""-214""')], (229"-233:232"-236)-bisdisulfide

STRUCTURAL FORMULA

Heavy chain (anti-CD20)

EVQLVESGGG	LVQPGRSLRL	SCVASGFTFN	DYAMHWVRQA	PGKGLEWVSV	50
ISWNSDSIGY	ADSVKGRFTI	SRDNAKNSLY	LQMHSRAED	TALYYCAKDN	100
HYGSGSYYY	QYGMVWVWQG	TTVTVSSAST	KGPSVFPLAP	CSRSTSESTA	150
ALGCLVKDYF	PEPVTVSWNS	GALTSQVHTF	PAVLQSSGLY	SLSSVVTVPS	200
SSLGTTKTYTC	NVDHKPSNTK	VDKRVESKYG	PPCPPCPAPP	VAGPSVFLFP	250
PKPKDTLMIS	RTPEVTCVVV	DVSQEDPEVQ	FNWYVDGVEV	HNAKTKPREE	300
QFNSTYRVVS	VLTVLHQDWL	NGKEYKCKVS	NKGLPSSIEK	TISKAKGQPR	350
EPQVYTLPPS	QEEMTKNQVS	LTCLVKGFYP	SDIAVEWESN	GQPENNYKTT	400
PPVLDSDGSF	FLYSRLTVDK	SRWQEGNVFS	CSVMHEALHN	HYTQKSLSL	450
LGK					453

Heavy chain (anti-CD3)

EVQLVESGGG	LVQPGRSLRL	SCAASGFTFD	DYTMHWVRQA	PGKGLEWVSG	50"
ISWNSGSIY	ADSVKGRFTI	SRDNAKNSLY	LQMNSRAED	TALYYCAKDN	100"
SGYGHYYGM	DVWGQGTTVT	VASASTKGPS	VFPLAPCSR	TSESTAALGC	150"
LVKDYFPPEV	TVSWNSGALT	SGVHTFPAVL	QSSGLYSLSS	VVTVPSSSLG	200"
TKTYTCNVDH	KPSNTKVDKR	VESKYGPPCP	PCPAPPVAGP	SVFLFPPKPK	250"
DTLMISRTPE	VTCVVVDVDSQ	EDPEVQFNWY	VDGVEVHNAK	TKPREEQFNS	300"
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKGL	PSSIEKTIK	AKGQPREPQV	350"
YTLPPSQEEM	TKNQVSLTCL	VKGFYPSDIA	VEWESNGQPE	NNYKTTTPVL	400"
DSDGSFFLYS	RLTVDKSRWQ	EGNVFSCSVM	HEALHNRFTQ	KSLSLSLGK	449"

Light chains

EIVMTQSPAT	LSVSPGERAT	LSCRASQSVS	SNLAWYQQKP	GQAPRLLIYG	50'
ASTRATGIPA	RFSGSGSGTE	F'TLT'ISSLQS	EDFAVYYCQH	YINWPLTFGG	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges

22-96	22"-96"	23'-88'	23'''-88'''	134'-194'	134'''-194'''	137"-214"	141-214'
150"-206"	154-210	229"-233	232"-236	263"-323"	267-327	369"-427"	373-431

Glycosylation sites (N)

Asn-299" Asn-303

MOLECULAR FORMULA	C ₆₄₅₈ H ₉₉₅₀ N ₁₇₂₈ O ₂₀₂₀ S ₄₆
MOLECULAR WEIGHT	145.6 kDa (non-glycosylated)
TRADEMARK	None as yet
SPONSOR	Regeneron Pharmaceuticals
CODE DESIGNATIONS	REGN1979
<u>CAS</u> REGISTRY NUMBER	1801338-64-6
UNII	8R5CM46UIO
WHO NUMBER	11035

gbk